PPARγ is functionally expressed in clear cell renal cell carcinoma

  • Authors:
    • Nicolas Collet
    • Sandrine Théoleyre
    • Julie Rageul
    • Stéphanie Mottier
    • Florence Jouan
    • Nathalie Rioux-Leclercq
    • Patricia Fergelot
    • Jean-Jacques Patard
    • Damien Masson
    • Marc G. Denis
  • View Affiliations

  • Published online on: December 28, 2010     https://doi.org/10.3892/ijo.2010.891
  • Pages: 851-857
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) agonists have been demonstrated to exert an inhibitory effect on cell growth in several tumor models, including clear cell renal cell carcinoma (CCRCC). PPARγ has therefore been proposed to be a potential therapeutic target. Thus, the PPARγ gene must be expressed and not altered in cancer cells. We have therefore analyzed tumor specimens collected from 63 patients with CCRCC who underwent partial or total nephrectomy. The multiplex ligation-dependent probe amplification (MLPA) assay was used to detect deletions in the PPARγ gene. The majority of the tumors (48/63; 76.2%) did not present alterations. Two samples (3.2%) presented a deletion of the non-coding exon A1. Nine samples (14.3%) showed large heterozygous deletions in chromosome 3p including PPARγ. Potential mutations were analyzed by DNA sequencing of the 6 coding exons of the PPARγ gene. No mutation was found in exons 1-5. In exon 6, a silent polymorphism was detected in 14 samples (22.2%). CCRCC were found to express the PPARγ1 isoform. The expression level of PPARγ was measured by real-time quantitative PCR. A significantly reduced transcript level was associated with an elevated Fuhrman grade. Finally, we analyzed the expression of angiopoietin-like 4, a known PPARγ target gene, in CCRCC cell lines cultured in the presence of rosiglitazone, a PPARγ agonist. A strong induction was found in the 3 cell lines tested, indicating that PPARγ is functional in all these cell lines. In conclusion, we show here that PPARγ is expressed and functional in CCRCC, prerequisites for being a potential target for CCRCC treatment.

Related Articles

Journal Cover

March 2011
Volume 38 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Collet N, Théoleyre S, Rageul J, Mottier S, Jouan F, Rioux-Leclercq N, Fergelot P, Patard J, Masson D, Denis MG, Denis MG, et al: PPARγ is functionally expressed in clear cell renal cell carcinoma. Int J Oncol 38: 851-857, 2011
APA
Collet, N., Théoleyre, S., Rageul, J., Mottier, S., Jouan, F., Rioux-Leclercq, N. ... Denis, M.G. (2011). PPARγ is functionally expressed in clear cell renal cell carcinoma. International Journal of Oncology, 38, 851-857. https://doi.org/10.3892/ijo.2010.891
MLA
Collet, N., Théoleyre, S., Rageul, J., Mottier, S., Jouan, F., Rioux-Leclercq, N., Fergelot, P., Patard, J., Masson, D., Denis, M. G."PPARγ is functionally expressed in clear cell renal cell carcinoma". International Journal of Oncology 38.3 (2011): 851-857.
Chicago
Collet, N., Théoleyre, S., Rageul, J., Mottier, S., Jouan, F., Rioux-Leclercq, N., Fergelot, P., Patard, J., Masson, D., Denis, M. G."PPARγ is functionally expressed in clear cell renal cell carcinoma". International Journal of Oncology 38, no. 3 (2011): 851-857. https://doi.org/10.3892/ijo.2010.891